PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.

Abstract We report the long-term tumor control and toxicity outcomes of patients undergoing hypofractionated (2.2 Gy) image-guided intensity-modulated radiotherapy (IG-IMRT) using tomotherapy for clinically localized prostate cancer.
PMID
Related Publications

Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.

Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.

Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.

Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.

Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.

Authors

Mayor MeshTerms

Dose Hypofractionation

Keywords

Tomotherapy

image-guided intensity-modulated radiotherapy

prostate cancer

Journal Title anticancer research
Publication Year Start




PMID- 28982908
OWN - NLM
STAT- MEDLINE
DCOM- 20171016
LR  - 20171016
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 10
DP  - 2017 Oct
TI  - Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer
      Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided
      Intensity-modulated Radiotherapy.
PG  - 5829-5835
AB  - AIM: We report the long-term tumor control and toxicity outcomes of patients
      undergoing hypofractionated (2.2 Gy) image-guided intensity-modulated
      radiotherapy (IG-IMRT) using tomotherapy for clinically localized prostate
      cancer. PATIENTS AND METHODS: We examined the cases of 138 consecutive patients
      with stage T1-T3 prostate cancer that were treated with IG-IMRT from June 2007 to
      July 2009. The median follow-up time was 79 months (range=31-96 months). The
      planning target volume received a dose of 72.6-74.8 Gy in 33-34 fractions (2.2
      Gy/fraction). Megavoltage computed tomographic (CT) scans were performed before
      each treatment and corrected to the registered positions on the planning CT scans
      using prostate soft-tissue matching. RESULTS: The 5-year biochemical and clinical
      relapse-free survival rates were 95% for the low-risk group, 92% for the
      intermediate-risk group, and 77% for the high-risk group. The 5-year incidence
      rates of grade 2 and 3 late gastrointestinal toxicities were 6.3% and 3.1%,
      respectively, and those of grade 2 and 3 late genitourinary toxicities were 7.9% 
      and 0%, respectively. Multivariate analysis indicated that T-stage is a
      prognostic factor for biochemical relapse-free survival rates. CONCLUSION: This
      report involved the longest followed-up cohort of patients to have received
      hypofractionated (2.2 Gy) soft tissue-matched IG-IMRT using tomotherapy. The
      findings of this study indicate that hypofractionated IMRT is well tolerated and 
      is associated with good long-term tumor-control outcomes in patients with
      localized prostate cancer.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Shimizu, Daisuke
AU  - Shimizu D
AD  - Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan
      [email protected]
FAU - Yamazaki, Hideya
AU  - Yamazaki H
AD  - Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Nishimura, Takuya
AU  - Nishimura T
AD  - Department of Radiology, Kyoto first Red Cross Hospital, Kyoto, Japan.
FAU - Aibe, Norihiro
AU  - Aibe N
AD  - Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Okabe, Haruumi
AU  - Okabe H
AD  - Department of Radiology, Ujitakeda Hospital, Uji, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adenocarcinoma/diagnostic imaging/pathology/*radiotherapy
MH  - Disease-Free Survival
MH  - *Dose Hypofractionation
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Proportional Hazards Models
MH  - Prostatic Neoplasms/diagnostic imaging/pathology/*radiotherapy
MH  - Radiation Injuries/etiology
MH  - Radiographic Image Interpretation, Computer-Assisted
MH  - Radiotherapy, Image-Guided/adverse effects/*methods
MH  - Radiotherapy, Intensity-Modulated/adverse effects/*methods
MH  - Risk Factors
MH  - Time Factors
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Tomotherapy
OT  - *image-guided intensity-modulated radiotherapy
OT  - *prostate cancer
EDAT- 2017/10/07 06:00
MHDA- 2017/10/17 06:00
CRDT- 2017/10/07 06:00
PHST- 2017/07/27 00:00 [received]
PHST- 2017/08/16 00:00 [revised]
PHST- 2017/08/22 00:00 [accepted]
PHST- 2017/10/07 06:00 [entrez]
PHST- 2017/10/07 06:00 [pubmed]
PHST- 2017/10/17 06:00 [medline]
AID - 37/10/5829 [pii]
AID - 10.21873/anticanres.12026 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Oct;37(10):5829-5835. doi: 10.21873/anticanres.12026.